# Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery

> **NCT00445861** · PHASE1,PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 27 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **BIOLOGICAL:** cetuximab + docetaxel + cisplatin
- **BIOLOGICAL:** Treatment level 1
- **BIOLOGICAL:** Treatment level 2
- **PROCEDURE:** conventional surgery

## Key facts

- **NCT ID:** NCT00445861
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2012-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00445861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00445861, "Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00445861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*